相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report
Min Yu et al.
ANTI-CANCER DRUGS (2022)
Primary mediastinal large B-cell lymphoma
Kerry J. Savage
BLOOD (2022)
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B. Allen et al.
BLOOD (2021)
Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Elif Yilmaz et al.
BLOOD (2021)
Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway
Andres E. Quesada et al.
BREAST JOURNAL (2021)
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla et al.
LANCET ONCOLOGY (2021)
PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements
Rebeca Manso et al.
LEUKEMIA & LYMPHOMA (2021)
Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas
Karolina Bednarska et al.
BLOOD REVIEWS (2021)
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
Miso Kim et al.
HAEMATOLOGICA (2021)
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features
Jennifer R. Chapman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease
Mark G. Evans et al.
MODERN PATHOLOGY (2021)
EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency
Akira Satou et al.
CANCER MEDICINE (2021)
The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
Marcos Garcia-Lacarte et al.
CANCERS (2021)
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial
Alex F. Herrera et al.
BLOOD ADVANCES (2021)
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Estelle Bourbon et al.
BLOOD ADVANCES (2021)
Current and emerging treatment options in primary mediastinal B-cell lymphoma
Bita Fakhri et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma
Samer A. Al-Hadidi et al.
JCO ONCOLOGY PRACTICE (2021)
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song et al.
LEUKEMIA (2020)
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
Jing Shen et al.
MODERN PATHOLOGY (2020)
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL
Camille Laurent et al.
BLOOD (2020)
Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis
Miguel A. Piris et al.
PATHOLOGY (2020)
Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review
Mario L. Marques-Piubelli et al.
PATHOLOGY (2020)
Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression
Xiang-Nan Jiang et al.
ONCOIMMUNOLOGY (2020)
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
Masaharu Kawashima et al.
LEUKEMIA (2020)
T-cell lymphoma secondary to checkpoint inhibitor therapy
Kartik Anand et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
Wei Xie et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL
Emma I. Andersson et al.
CANCERS (2020)
PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
Yasumasa Ishida
CELLS (2020)
Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas
Alexander Neuwelt et al.
BLOOD ADVANCES (2020)
A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
Swami P. Iyer et al.
BLOOD (2020)
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault et al.
BLOOD ADVANCES (2020)
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
James Godfrey et al.
BLOOD (2019)
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma
Greg Hapgood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas
Keisuke Kataoka et al.
LEUKEMIA (2019)
STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma
Roberto Tamma et al.
TRANSLATIONAL ONCOLOGY (2019)
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
Shahrzad Jalali et al.
BLOOD CANCER JOURNAL (2019)
Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas
Valentina Tabanelli et al.
HUMAN PATHOLOGY (2019)
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening
Jing-Ping Zhang et al.
BLOOD (2019)
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
Anja Mottok et al.
BLOOD (2019)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen et al.
BLOOD (2019)
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers
Arantza Onaindia et al.
HAEMATOLOGICA (2019)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
Yuankai Shi et al.
LANCET HAEMATOLOGY (2019)
Efficacy of nivolumab in a patientwith systemic refractory ALK plus anaplastic large cell lymphoma
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2018)
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma
Enrico Tiacci et al.
BLOOD (2018)
Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
Anja Mottok et al.
BLOOD (2018)
Genetic subtyping of breast implant-associated anaplastic large cell lymphoma
Naoki Oishi et al.
BLOOD (2018)
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
Poonam K. Panjwani et al.
HUMAN PATHOLOGY (2018)
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements
Rebecca A. Luchtel et al.
BLOOD (2018)
Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma
Piers Blombery et al.
Oncotarget (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Hodgkin Lymphoma: A Review and Update on Recent Progress
Satish Shanbhag et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
Hyun Jung Kwon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
Elise A. Chong et al.
BLOOD (2017)
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
Tomas Jelinek et al.
IMMUNOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Christopher D. Carey et al.
BLOOD (2017)
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani et al.
BLOOD (2017)
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
Dohee Kwon et al.
HISTOPATHOLOGY (2016)
Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2016)
Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
Holger Hebart et al.
ANNALS OF INTERNAL MEDICINE (2016)
Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas
Lauren C. Chong et al.
BLOOD (2016)
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Konstantinos Georgiou et al.
BLOOD (2016)
Immune checkpoint blockade: Releasing the brake towards hematological malignancies
Yi Xia et al.
BLOOD REVIEWS (2016)
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
Sydney Dubois et al.
CLINICAL CANCER RESEARCH (2016)
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
Thomas Menter et al.
HUMAN PATHOLOGY (2016)
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma
Mark W. Clemens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
Wei Xing et al.
ONCOTARGET (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment
Alina Nicolae et al.
BLOOD (2015)
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
Junichi Kiyasu et al.
BLOOD (2015)
Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
Ramona Crescenzo et al.
CANCER CELL (2015)
Integrated Copy Number and Gene Expression Profiling Analysis of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma
Heejei Yoon et al.
GENES CHROMOSOMES & CANCER (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro
Lina Quan et al.
PLOS ONE (2015)
Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
Min Shi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphomaaEuro
A. S. Gerrie et al.
ANNALS OF ONCOLOGY (2014)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Edgardo R. Parrilla Castellar et al.
BLOOD (2014)
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
BLOOD (2014)
Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways
Harumi Kato et al.
CANCER SCIENCE (2014)
Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Yansheng Hao et al.
CLINICAL CANCER RESEARCH (2014)
Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma
Michela Boi et al.
BLOOD (2013)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
Leo I. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
King L. Tan et al.
BLOOD (2012)
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
George Vasmatzis et al.
BLOOD (2012)
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation
Mamta Gupta et al.
BLOOD (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation
Santiago Montes-Moreno et al.
MODERN PATHOLOGY (2012)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
Peter Borchmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Christian Steidl et al.
NATURE (2011)
Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
Tania Diaz et al.
PLOS ONE (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
Ryo Yamamoto et al.
CANCER SCIENCE (2009)
Increased programmed death-1+tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival
Simone Muenst et al.
HUMAN PATHOLOGY (2009)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
U Holtick et al.
LEUKEMIA (2005)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
KJ Savage et al.
BLOOD (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
